Donepezil is a medication used in the palliative treatment of Alzheimer's disease. Donepezil is used to improve cognition and behavior of people with Alzheimer's, but does not slow the progression of or cure the disease.
Common side effects include loss of appetite, gastrointestinal upset, diarrhea, difficulty sleeping, vomiting, or muscle cramping.
The classification of Donepezil includes 5mg, 10mg and 23mg, and the proportion of 10mg in 2017 is about 48%.
North America is the largest consumption region of Donepezil, with a sales market share nearly 37% in 2017. Europe is the second largest consumption region of Donepezil, enjoying Sales market share nearly 29% in 2017.
Donepezil was developed by Eisai and Pfizer and is sold as a generic by multiple suppliers. Donepezil acts as a centrally acting reversible acetylcholinesterase inhibitor.
According to this study, over the next five years the Donepezil market will register a -1.6% CAGR in terms of revenue, the global market size will reach US$ 830 million by 2024, from US$ 920 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Donepezil business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Donepezil market by product type, application, key manufacturers and key regions and countries.
This study considers the Donepezil value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3: and forecast to 2024 in section 11.7.
5mg
10mg
23mg
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4: and forecast to 2024 in section 11.8.
Hospitals
Clinics
Drugstore
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Eisai
Pfizer
Teva
Sandoz
Apotex
Dr Reddy's Laboratories
Sun Pharmaceutical?
Hansoh Pharma
Cipla
ARK PHA.LTD
Jishengtang Pharma
Luoxin
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Donepezil consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Donepezil market by identifying its various subsegments.
Focuses on the key global Donepezil manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Donepezil with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Donepezil submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
